Novo Nordisk A/S (NEO:NVON)

Canada flag Canada · Delayed Price · Currency is CAD
5.78
-0.13 (-2.20%)
Sep 8, 2025, 9:42 AM EDT
-2.20%
Market Cap338.45B
Revenue (ttm)66.98B
Net Income (ttm)23.85B
Shares Outn/a
EPS (ttm)5.36
PE Ratio14.19
Forward PE14.31
Dividendn/a
Ex-Dividend Daten/a
Volume55,580
Average Volume75,462
Open5.83
Previous Close5.91
Day's Range5.68 - 5.83
52-Week Range4.83 - 10.80
Betan/a
RSI44.49
Earnings DateNov 5, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]

Industry Pharmaceutical Preparations
Founded 1923
Employees 77,349
Stock Exchange Cboe Canada
Ticker Symbol NVON
Full Company Profile

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK Financial Statements

News

There is no news available yet.